Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era-Reference-Cited by-同舟云学术

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

Published:2010-08 Issue:8 Volume:5 Page:1185-1196
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ahn Myung-Ju,Lee Jeeyun,Park Yun-Hee,Ahn Jin-Seok,Ziogas Argyrios,Zell Jason A.,Park Keunchil,Ignatius Ou Sai-Hong

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer;Hechet;Nat Rev Cancer,2003

2. Global cancer statistics;Parkin;CA Cancer J Clin,2002

3. Lung cancer in never smokers—a different disease;Sun;Nature,2007

4. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan;Takano;J Clin Oncol,2008

5. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras;Kim;Oncology,2009

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis;Lung Cancer;2023-08

2. Racial and ethnic disparities in nasopharyngeal cancer with an emphasis among Asian Americans;International Journal of Cancer;2022-06-22

3. The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study;Frontiers in Oncology;2021-07-07

4. International and global issues – differences in health systems, patient populations, and medical practice;Pragmatic Randomized Clinical Trials;2021

5. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis;Cancer Treatment and Research Communications;2021